Parvovirus B19 myocarditis in children: an observational study

Vigneswaran, Trisha V.; Brown, Julianne R.; Breuer, Judith; Burch, Michael

doi:10.1136/archdischild-2014-308080

Cited by 32 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In accord with these results, viral presence had no influence on outcome in another study . In contrast, other studies have reported an association between B19V infection of the heart and high morbidity and mortality . The above results demonstrate that large gaps in knowledge still exist in cardiac B19V infection and children.…”

Section: Parvovirus B19‐related Heart Disease In Childrensupporting

confidence: 66%

See 1 more Smart Citation

Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature

Verdonschot

Hazebroek

Merken

et al. 2016

European J of Heart Fail

129

121

View full text Add to dashboard Cite

Over the last decade, parvovirus B19 (B19V) has frequently been linked to the pathogenesis of myocarditis (MC) and its progression towards dilated cardiomyopathy (DCM). The exact role of the presence of B19V and its load remains controversial, as this virus is also found in the heart of healthy subjects. Moreover, the prognostic relevance of B19V prevalence in endomyocardial biopsies still remains unclear. As a result, it is unclear whether the presence of B19V should be treated. This review provides an overview of recent literature investigating the presence of B19V and its pathophysiological relevance in MC and DCM, as well as in normal hearts. In brief, no difference in B19V prevalence is observed between MC/DCM and healthy control hearts. Therefore, the question remains open whether and how cardiac B19V may be of pathogenetic importance. Findings suggest that B19V is aetiologically relevant either in the presence of other cardiotropic viruses, or when B19V load is high and/or actively replicating, which both may maintain myocardial (low-grade) inflammation. Therefore, future studies should focus on the prognostic relevance of the viral load, replicative status and virus co-infections. In addition, the immunogenetic background of MC/DCM patients that makes them susceptible to develop heart failure upon presence of B19V should be more thoroughly investigated.

show abstract

Section: Parvovirus B19‐related Heart Disease In Childrensupporting

confidence: 66%

“…Clinical presentation of B19V‐related MC or heart failure in children is often more severe compared with adult presentation and outcome . However, EMB is performed infrequently in children with suspected MC . Therefore, data regarding B19V in EMB in children are scarce and are often incomplete.…”

Section: Parvovirus B19‐related Heart Disease In Childrenmentioning

confidence: 99%

Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature

Verdonschot

Hazebroek

Merken

et al. 2016

European J of Heart Fail

129

121

View full text Add to dashboard Cite

show abstract

“…B19V infection, detected most often by serological evidence of recent infection and sometimes by the detection of viral genomes in cardiac tissue, has been reported in myocarditis in the fetus (see the section on hydrops below), in infancy, during childhood, and among young adults (174,176,(832)(833)(834)(835)(836)(837)(838)(839)(840). In one center's series of 19 pediatric patients, the presenting symptoms were upper respiratory and gastrointestinal symptoms; all infected children had ventricular dysfunction, 2 died, and 3 required heart transplantation (176).…”

Section: Clinical Manifestations Diseases Caused By B19v Infectionmentioning

confidence: 99%

Human Parvoviruses

2017

View full text Add to dashboard Cite

Parvovirus B19 (B19V) and human bocavirus 1 (HBoV1), members of the large Parvoviridae family, are human pathogens responsible for a variety of diseases. For B19V in particular, host features determine disease manifestations. These viruses are prevalent worldwide and are culturable in vitro, and serological and molecular assays are available but require careful interpretation of results. Additional human parvoviruses, including HBoV2 to -4, human parvovirus 4 (PARV4), and human bufavirus (BuV) are also reviewed. The full spectrum of parvovirus disease in humans has yet to be established. Candidate recombinant B19V vaccines have been developed but may not be commercially feasible. We review relevant features of the molecular and cellular biology of these viruses, and the human immune response that they elicit, which have allowed a deep understanding of pathophysiology.

show abstract

“…Interestingly, two peaks in occurrence were noted: in infants <1 year and in teenagers. Myocarditis in newborns is mainly caused by viral infection, such as enterovirus, parvovirus, or adenovirus (11).…”

Section: Indicationsmentioning

confidence: 99%

Neonatal Cardiac ECMO in 2019 and Beyond

Roeleveld

Mendonca

2019

Front. Pediatr.

View full text Add to dashboard Cite

Worldwide, the use of Extracorporeal Membrane Oxygenation (ECMO) for cardiac failure has been steadily increasing in the neonatal population and has become a widely accepted modality. Especially in centers caring for children with (congenital) heart disease, ECMO is now an essential part of care available for those with severe heart failure as a bridge to recovery, long term mechanical support, or transplantation. Short-term outcomes depend very much on indication. Hospital survival is ~40% for all neonatal cardiac ECMO patients combined. ECMO is being used for pre- and/or post-operative stabilization in neonates with congenital heart disease and in neonates with medical heart disease such as myocarditis, cardiomyopathy or refractory arrhythmias. ECMO use during resuscitation (ECPR) or for sepsis is summarized elsewhere in this special edition of Frontiers in Pediatrics. In this review article, we will discuss the indications for neonatal cardiac ECMO, the difficult process of patients' selection and identifying the right timing to initiate ECMO, as well as outline pros and cons for peripheral vs. central cannulation. We will present predictors of mortality and, very importantly, predictors of survival: what can be done to improve the outcomes for your patients. Furthermore, an overview of current insights regarding supportive care in neonatal cardiac ECMO is given. Additionally, we will address issues specific to neonates with single ventricle physiology on ECMO, for example cannulation strategies and the influence of shunt type (Blalock-Taussig shunt vs. “right ventricle to pulmonary artery” shunt). We will not only focus on short term outcomes, such as hospital survival, but also on the importance of long-term neuro-developmental outcomes, and we will end this review with suggestions for future research.

show abstract

Parvovirus B19 myocarditis in children: an observational study

Cited by 32 publications

References 31 publications

Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature

Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature

Human Parvoviruses

Neonatal Cardiac ECMO in 2019 and Beyond

Contact Info

Product

Resources

About